Literature DB >> 10547607

Heparin-binding EGF-like growth factor is expressed by mesangial cells and is involved in mesangial proliferation in glomerulonephritis.

T Takemura1, Y Murata, S Hino, M Okada, H Yanagida, M Ikeda, K Yoshioka.   

Abstract

Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a new member of the EGF family, is mitogenic for several types of cells, through binding to cell surface heparan sulphate proteoglycans. This study has attempted to delineate HB-EGF expression by mesangial cells and to identify its role in experimental and human glomerulonephritis. Rat mesangial cells, cultured in the presence of phorbol acetate, hydrogen peroxide, interleukin-1beta, and tumour necrosis factor-alpha, expressed HB-EGF mRNA. Recombinant HB-EGF stimulated rat mesangial cells to proliferate and to express types I and III collagen. In the rat anti-Thy-1.1 nephritis, glomerular HB-EGF mRNA was up-regulated and peaked at days 5-7; its expression at the protein level in the glomerulus was prominent at days 5-10. By immunofluorescence, HB-EGF was positive predominantly in the mesangial area of renal tissues from 23 of 45 patients with various types of human glomerulonephritis, showing a significant correlation with the grade of mesangial proliferation; there was no staining in tissues from patients with minimal change nephrotic syndrome and normal kidney tissues. These data provide the evidence that HB-EGF is synthesized and expressed by mesangial cells and stimulates mesangial cell proliferation and collagen synthesis in vitro. HB-EGF is a potential mediator in mesangial cell proliferation and matrix expansion in experimental and human glomerulonephritis. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547607     DOI: 10.1002/(SICI)1096-9896(199911)189:3<431::AID-PATH460>3.0.CO;2-I

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  6 in total

Review 1.  Role of EGF receptor signaling on morphogenesis of eyelid and meibomian glands.

Authors:  Fei Dong; Mindy Call; Ying Xia; Winston W-Y Kao
Journal:  Exp Eye Res       Date:  2017-10       Impact factor: 3.467

2.  Heme oxygenase-1 modulates mesangial cell proliferation by p21 Waf1 upregulation.

Authors:  Dileep Kumar; Madhu Bhaskaran; Lakshmi Alagappan; Dipti Tori; Iti Yadav; Sridevi Konkimalla; Sandip Magoon; Pravin C Singhal
Journal:  Ren Fail       Date:  2010-01       Impact factor: 2.606

3.  Antiproliferative effect of fluvastatin and thiazolidinedione in mesangial cells of diabetic rats.

Authors:  Mitsuru Okada; Hidehiko Yanagida; Hiroaki Kuwajima; Tsukasa Takemura
Journal:  Pediatr Nephrol       Date:  2003-11-22       Impact factor: 3.714

4.  Obesity and kidney disease: Beyond the hyperfiltration.

Authors:  A Mascali; O Franzese; S Nisticò; U Campia; D Lauro; C Cardillo; N Di Daniele; M Tesauro
Journal:  Int J Immunopathol Pharmacol       Date:  2016-04-04       Impact factor: 3.219

5.  Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis.

Authors:  Guillaume Bollée; Martin Flamant; Sandra Schordan; Cécile Fligny; Elisabeth Rumpel; Marine Milon; Eric Schordan; Nathalie Sabaa; Sophie Vandermeersch; Ariane Galaup; Anita Rodenas; Ibrahim Casal; Susan W Sunnarborg; David J Salant; Jeffrey B Kopp; David W Threadgill; Susan E Quaggin; Jean-Claude Dussaule; Stéphane Germain; Laurent Mesnard; Karlhans Endlich; Claude Boucheix; Xavier Belenfant; Patrice Callard; Nicole Endlich; Pierre-Louis Tharaux
Journal:  Nat Med       Date:  2011-09-25       Impact factor: 53.440

6.  A miR-1207-5p binding site polymorphism abolishes regulation of HBEGF and is associated with disease severity in CFHR5 nephropathy.

Authors:  Gregory Papagregoriou; Kamil Erguler; Harsh Dweep; Konstantinos Voskarides; Panayiota Koupepidou; Yiannis Athanasiou; Alkis Pierides; Norbert Gretz; Kyriacos N Felekkis; Constantinos Deltas
Journal:  PLoS One       Date:  2012-02-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.